Last $0.03 USD
Change Today +0.0032 / 10.39%
Volume 25.0K
RAFA On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

rafarma pharmaceuticals inc (RAFA) Key Developments

Rafarma Pharmaceuticals Inc. Appoints Mr. Bruno Horn as New President and Director

Rafarma Pharmaceuticals Inc. announced appointment of Mr. Bruno Horn as the new President and Director of the company, effective July 15, 2014. Mr. Horn is the founder of his own consultancy based in Switzerland, specializing in steel trading and the pharmaceutical industry.

Rafarma Pharmaceuticals Announces the Complete Restructuring of Existing EUR 90,000,000 Loan with VNeshconombank

Rafarma Pharmaceuticals Inc. announced the complete restructuring of its existing EUR 90,000,000.00 loan with VNeshconombank (VEBank). Terms and conditions of the restructured loan include a 3-year deferment, or holiday, on all principal and interest payments thus greatly enhancing the financial stability of the company.

Rafarma Pharmaceuticals, Inc. Enters New Distribution Agreement with Amber Pharma Distribution Group

Rafarma Pharmaceuticals, Inc. announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group.

New Dialysis Research and Development Center of Rafarma Pharmaceuticals, Inc. Devotes to Dialysis Research and Product Development

The success of Rafarma Pharmaceuticals, Inc. in choosing Terbuny for its facility has attracted more biotech companies to the area. A new facility specifically devoted to dialysis research and product development has been announced. The new facility will be located near Rafarma's already-operating pharmaceutical plant in Terbuny in the Lipetsk region of Russia, a few hours south from Moscow. Rafarma and the dialysis facility plan to work in close cooperation in the development of dialysis-specific products. Terbuny is part of a special economic development region to promote economic growth and jobs in the area. For building and maintaining its facilities in Terbuny, as well as hiring local residents, Rafarma enjoys specific government incentives which enhance its bottom line.

Rafarma Pharmaceuticals, Inc. Announces Cooperative Research and Development Effort with Christian Albrecht University in Kiel, Germany

Rafarma Pharmaceuticals, Inc. announced a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects: The development of innovative Liposomal forms, anti-cancer and anti-tuberculosis drugs with certain targeted pharmacokinetic characteristics. The goal is to create parenteral medications based on non-dissolvable pharmaceutical substances using encapsulation and liposomes; The development of products with higher bioavailability (thereby increasing absorption rates) through modification of biopharmaceutical characteristics. The modifications are achieved by the creation of nano-crystals, which are formed through size reduction in the gas phase, as well as through synthetic crystallization.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RAFA:US $0.03 USD +0.0032

RAFA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RAFA.
View Industry Companies
 

Industry Analysis

RAFA

Industry Average

Valuation RAFA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAFARMA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.